Feb 21, 2017

Sarepta sells fast-track drug voucher to Gilead for $125 million

Wikimedia Creative Commons

Sarepta Therapeutics announced this morning it will sell its rare pediatric disease priority review voucher to Gilead Sciences for $125 million, giving Gilead the rights to have one of its drugs receive fast-track approval from the Food and Drug Administration.

The vouchers let drug companies get a decision on their medicines within six months, rather than the standard 10-plus months. The FDA awarded Sarepta the voucher last year at the same time the agency green-lighted Sarepta's drug that treats Duchenne muscular dystrophy, a move that was controversial at the time because there was disagreement over whether the drug was beneficial. Sarepta still has to conduct a clinical trial to back up the benefits of that drug.

Why this matters: Priority review vouchers have become valuable commodities as drug companies look for ways to jump ahead in the FDA line. There have been a handful of transactions in the decade that vouchers have been around. But Sarepta's $125 million deal fetched a lower price than the two most recent voucher sales of $350 million and $245 million. Analysts at investment bank Leerink Partners thought Sarepta could have gotten at least $200 million, raising questions of whether there is a "broader decline" of interest in the vouchers that command "increasingly astronomical" price tags.

Go deeper

Axios Dashboard

Keep up with breaking news throughout the day β€” sign up for our alerts.

Fear of coronavirus pandemic escalates

Photo: Abdulgani Basheer/AFP/Getty Images

In the blink of an eye, we've entered a new phase on the coronavirus.

The big picture: Italy, Iran and South Korea are at "decisive" points in their responses, the World Health Organization said on Thursday.

Go deeperArrow2 hours ago - Health

Stocks fall 4% as sell-off worsens

A trader on the floor of the New York Stock Exchange. Photo: Johannes Eisele/AFP via Getty Images

Stocks fell more than 4% on Thursday, extending the market’s worst week since the financial crisis in 2008 following a spike in coronavirus cases around the world.

The big picture: All three indices are in correction, down over 10% from recent record-highs, amid a global market rout. It's the S&P 500's quickest decline into correction territory in the index's history, per Deutsche Bank.

Go deeperArrowUpdated 2 hours ago - Economy & Business